Hurwitz H, et al. - In a subgroup analysis of patients with metastatic pancreatic cancer and systemic inflammation (C-reactive protein [CRP] >13 mg/dL) in the randomized phase II RECAP study, improved overall survival (OS) was afforded by ruxolitinib, a Janus kinase 1 (JAK1)/JAK2 inhibitor, plus capecitabine as compared with capecitabine. Herein, the results from two randomized phase III studies, JANUS 1 and JANUS 2, were reported. Findings demonstrated that ruxolitinib + capecitabine failed to improve survival but was well tolerated in refractory pancreatic cancer patients.